BR112021022135A2 - Anticorpos biespecíficos contra chi3l1 e pd1 com efeitos citotóxicos mediados por célula t realçados sobre células de tumor - Google Patents

Anticorpos biespecíficos contra chi3l1 e pd1 com efeitos citotóxicos mediados por célula t realçados sobre células de tumor

Info

Publication number
BR112021022135A2
BR112021022135A2 BR112021022135A BR112021022135A BR112021022135A2 BR 112021022135 A2 BR112021022135 A2 BR 112021022135A2 BR 112021022135 A BR112021022135 A BR 112021022135A BR 112021022135 A BR112021022135 A BR 112021022135A BR 112021022135 A2 BR112021022135 A2 BR 112021022135A2
Authority
BR
Brazil
Prior art keywords
antibodies
chi3l1
bispecific
enhanced
cytotoxic effects
Prior art date
Application number
BR112021022135A
Other languages
English (en)
Inventor
A Elias Jack
Geun Lee Chun
Kamle Suchitra
Original Assignee
Univ Brown
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Brown filed Critical Univ Brown
Publication of BR112021022135A2 publication Critical patent/BR112021022135A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

ANTICORPOS BIESPECÍFICOS CONTRA CHI3L1 E PD1 COM EFEITOS CITOTÓXICOS MEDIADOS POR CÉLULA T REALÇADOS SOBRE CÉLULAS DE TUMOR. São aqui descritos anticorpos biespecíficos simultaneamente alvejando tanto CHI3L1 quanto a molécula do ponto de checagem imunológico PD-1. Estes anticorpos manifestam efeitos citotóxicos sinergísticos realçados comparados com os efeitos dos anticorpos de CHI3L1 e PD-1 individuais, sozinhos ou em combinação. Métodos para tratar um câncer pela administração dos anticorpos biespecíficos também são aqui descritos providos.
BR112021022135A 2019-05-06 2020-05-06 Anticorpos biespecíficos contra chi3l1 e pd1 com efeitos citotóxicos mediados por célula t realçados sobre células de tumor BR112021022135A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962843931P 2019-05-06 2019-05-06
US201962876507P 2019-07-19 2019-07-19
US201962898324P 2019-09-10 2019-09-10
PCT/US2020/031710 WO2020227431A1 (en) 2019-05-06 2020-05-06 Bispecific antibodies against chi3l1 and pd1 with enhanced t cell-mediated cytotoxic effects on tumor cells

Publications (1)

Publication Number Publication Date
BR112021022135A2 true BR112021022135A2 (pt) 2023-02-28

Family

ID=73050712

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021022135A BR112021022135A2 (pt) 2019-05-06 2020-05-06 Anticorpos biespecíficos contra chi3l1 e pd1 com efeitos citotóxicos mediados por célula t realçados sobre células de tumor

Country Status (8)

Country Link
US (1) US20220213193A1 (pt)
EP (1) EP3966247A4 (pt)
JP (1) JP2022531444A (pt)
CN (1) CN114008078A (pt)
AU (1) AU2020267491A1 (pt)
BR (1) BR112021022135A2 (pt)
CA (1) CA3139086A1 (pt)
WO (1) WO2020227431A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3118890A1 (en) * 2018-11-07 2020-05-14 Brown University Methods and compositions relating to anti-chi3l1 antibody reagents for the treatment of fibrosis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014012819B1 (pt) * 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
SI2794658T1 (sl) * 2011-12-19 2017-05-31 Synimmune Gmbh Bispecifična molekula protitelesa
US20160145355A1 (en) * 2013-06-24 2016-05-26 Biomed Valley Discoveries, Inc. Bispecific antibodies
MX2020000055A (es) * 2017-07-06 2020-08-06 Merus Nv Anticuerpos biespecificos antiproteina 1 de muerte celular programada (pd-1) -anti inmunoglobulina de celulas t y dominio de mucina que contiene -3 (tim-3).
US10766968B2 (en) * 2017-08-23 2020-09-08 Brown University Methods and compositions relating to anti-CHI3L1 antibody reagents to treat cancer
US11421029B2 (en) * 2017-09-01 2022-08-23 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Recombinant bispecific antibodies to PD-L1 and CTLA-4
CN109575139A (zh) * 2017-09-29 2019-04-05 上海药明生物技术有限公司 针对表皮生长因子受体和程序性死亡受体的双特异抗体
EP3692073A4 (en) * 2017-10-03 2021-05-26 Cedars-Sinai Medical Center METHOD OF TARGETING THE IMMUNE CHECK POINT PD1 SIGNAL PATH FOR TREATMENT OF LUNG FIBROSIS

Also Published As

Publication number Publication date
WO2020227431A1 (en) 2020-11-12
EP3966247A1 (en) 2022-03-16
US20220213193A1 (en) 2022-07-07
EP3966247A4 (en) 2023-01-04
JP2022531444A (ja) 2022-07-06
CA3139086A1 (en) 2020-11-12
CN114008078A (zh) 2022-02-01
AU2020267491A1 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
MX2019002474A (es) Composiciones de agente de unión de portador-ligando-1 de muerte programada y métodos de uso de las mismas para el tratamiento de cánceres.
CY1124791T1 (el) Μορια δεσμευσης ειδικα για cd73 και χρησεις αυτων
PH12019501663A1 (en) Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate
CO2021016552A2 (es) Conjugados de anticuerpo-fármaco inhibidores de mcl-1 y sus métodos de uso
PH12019502545A1 (en) Anti-cdh6 antibody and anti-cdh6 antibody-drug conjugate
BR112019008854A2 (pt) ligantes contendo peptídeo para conjugados de anticorpo-fármaco
SG10201902380SA (en) Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases
MY197324A (en) Adenovirus armed with bispecific t cell activator
WO2017079746A3 (en) Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
MX2018013848A (es) Combinacion de anticuerpos anti-pd-1s y radiacion para tratar cancer.
MX2019008207A (es) Métodos para tratar el cáncer con anticuerpos anti-pd-1.
WO2016106403A3 (en) Therapeutic compositions and methods for malignant tumors with rnai molecules targeted to hsp47 and p21
MX2019013690A (es) Conjugados de farmaco-proteina con ciclodextrina.
EA202190181A1 (ru) Композиции и способы для направленной иммунотерапии flt3, pd-1 и/или pd-l1
BR112018013407A2 (pt) anticorpos e conjugados dos mesmos
MX2022015748A (es) Uso de una molecula anti-b7-h3 en combinacion con una molecula anti-pd-1 en la preparacion de formulaciones para el tratamiento de cancer.
BR112015005772A2 (pt) método para a intensificação de imunoterapias específicas no tratamento de câncer
MX2022001732A (es) Metodos y composiciones para promover y potenciar la respuesta inmunitaria mediada por linfocitos t dirigida a la adcc de las celulas con expresion de cd39.
NZ718148A (en) Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma
MX2016009284A (es) Construcciones dirigidas a receptor y sus usos.
WO2020018996A3 (en) Delivery of sialidase to cancer cells, immune cells and the tumor microenvironment
WO2018098352A3 (en) Targeting kras induced immune checkpoint expression
BR112019024719A2 (pt) Composições e métodos para resposta imunológica antitumor aprimorada
BR112022026236A2 (pt) Terapia de combinação de imuno-oncologia com conjugados de il-2 e anticorpos anti-egfr
EA201690321A1 (ru) Применение иммуноконъюгата антитела к muc1 и майтанзиноида для лечения солидных опухолей